Study of Trilaciclib and Lurbinectidin
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and atezolizumab. While response rates for this regimen are high (roughly 60%), the duration of response is short, typically 4 months. Following progression after the 1st line treatment of SCLC, there is no consensus regarding subsequent therapy. Lurbinectedin is FDA approved and is increasingly preferred in clinical practice. Toxicity was significant, but appeared favorable compared to historic results with topotecan, leading to the adoption of this therapy for second-line SCLC. The toxicity profile was dominated by myelosuppression. This study investigates the effect of Trilaciclib on myelosuppression rate in subjects with platinum refractory extensive stage (ES)- SCLC receiving Lurbinectedin as well as the clinical synergy of Trilaciclib and Lurbinectedin combination.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek minimum 18 lat
- •Podpisana świadoma zgoda na uczestnictwo w badaniu
- •Ogólny stan zdrowia pozwalający na aktywność przez większość dnia (ECOG 0-1)
- •Widoczne zmiany nowotworowe zmierzone w ciągu 4 tygodni przed rozpoczęciem leczenia
- •Poprzednia terapia lekami na bazie platyny, lekami anty-PD1 lub anty-PDL1
✗ Disqualifies
- •Aktywna infekcja wymagająca leczenia
- •Ciąża lub karmienie piersią
- •Stosowanie innego eksperymentalnego leku w ciągu 4 tygodni przed leczeniem
- •Alergia na którykolwiek ze składników badanych leków
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Dartmouth Hitchcock Medical Center
Lebanon, United States
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
Chapel Hill, United States
Trial contact
Shamina Williams
Lauren Higgins
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.